[go: up one dir, main page]

AR013981A1 - Terapia de progestina con hemorragia controlada - Google Patents

Terapia de progestina con hemorragia controlada

Info

Publication number
AR013981A1
AR013981A1 ARP980105256A ARP980105256A AR013981A1 AR 013981 A1 AR013981 A1 AR 013981A1 AR P980105256 A ARP980105256 A AR P980105256A AR P980105256 A ARP980105256 A AR P980105256A AR 013981 A1 AR013981 A1 AR 013981A1
Authority
AR
Argentina
Prior art keywords
therapy
hemorragy
progestine
controlled
progestin
Prior art date
Application number
ARP980105256A
Other languages
English (en)
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of AR013981A1 publication Critical patent/AR013981A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invencion explica que el suministro de progestina en forma diaria, cíclica por vía vaginal puede ser usado para proporcionar unahemorragia premenopáusica predecible, regular durante la terapia de sustitucion de hormonas. La presenteinvencion también describe que la administracionconstante de progestina en un polímero de ácido policarboxílico entrecruzado no soluble al agua y que se hincha con el agua puede ser empleada para mantener laamenorrea. Cualquiera de los regímenes sea compana con una disminucion significativa de los efectos colaterales adversos.
ARP980105256A 1997-10-21 1998-10-22 Terapia de progestina con hemorragia controlada AR013981A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6348597P 1997-10-21 1997-10-21
US09/170,326 US6306914B1 (en) 1997-10-21 1998-10-13 Progestin therapy for maintaining amenorrhea

Publications (1)

Publication Number Publication Date
AR013981A1 true AR013981A1 (es) 2001-01-31

Family

ID=26743461

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105256A AR013981A1 (es) 1997-10-21 1998-10-22 Terapia de progestina con hemorragia controlada

Country Status (19)

Country Link
US (3) US6306914B1 (es)
EP (1) EP1032399A1 (es)
JP (1) JP2003535015A (es)
KR (1) KR100581308B1 (es)
CN (1) CN1147301C (es)
AR (1) AR013981A1 (es)
AU (1) AU742166C (es)
BR (1) BR9813262A (es)
CA (2) CA2307615A1 (es)
HU (1) HUP0004133A3 (es)
IL (1) IL135742A (es)
MX (1) MXPA00003972A (es)
MY (1) MY121743A (es)
NO (1) NO326856B1 (es)
NZ (1) NZ504066A (es)
PE (1) PE121799A1 (es)
RO (1) RO121319B1 (es)
RU (2) RU2261099C2 (es)
WO (1) WO1999020282A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
NZ591627A (en) * 2001-12-05 2012-09-28 Teva Womens Health Inc Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
AU2003239869A1 (en) * 2002-05-23 2003-12-12 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
AU2003297534A1 (en) * 2002-12-24 2004-07-22 Ovion, Inc. Contraceptive device and delivery system
EP1624848A4 (en) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE
US7855190B2 (en) * 2003-07-16 2010-12-21 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20050032758A1 (en) * 2003-06-25 2005-02-10 Ina Rudolph Hormone replacement therapy and depression
EP1761231A1 (en) * 2004-06-07 2007-03-14 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP1971325A2 (en) * 2005-12-27 2008-09-24 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
WO2007085020A2 (en) * 2006-01-20 2007-07-26 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
US8235047B2 (en) 2006-03-30 2012-08-07 Conceptus, Inc. Methods and devices for deployment into a lumen
AU2007256718A1 (en) * 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
GB0616444D0 (en) * 2006-08-18 2006-09-27 Reckitt Benckiser Nv Detergent composition
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
HUE035634T2 (en) * 2008-02-04 2018-05-28 Ferring Bv A monolithic monolith containing progesterone and a method for its preparation and use
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
RU2697369C1 (ru) * 2018-12-21 2019-08-13 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Способ дифференциальной диагностики функциональной гипоталамической аменореи на фоне стресса и энергетического дефицита
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN113288865B (zh) * 2021-06-28 2022-03-08 浙江仙琚制药股份有限公司 一种黄体酮阴道凝胶剂的制备方法
CN114983929A (zh) * 2022-05-16 2022-09-02 安徽万邦医药科技股份有限公司 一种稳定的黄体酮缓释凝胶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
USD345211S (en) 1992-04-06 1994-03-15 Columbia Laboratories, Inc. Dispensing vial for feminine hygiene products
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
USD375352S (en) 1994-03-14 1996-11-05 Columbia Laboratories, Inc. Dispensing vial for feminine hygiene products

Also Published As

Publication number Publication date
CA2649671A1 (en) 1999-04-29
NO20002084D0 (no) 2000-04-19
JP2003535015A (ja) 2003-11-25
KR100581308B1 (ko) 2006-05-22
NO20002084L (no) 2000-06-21
PE121799A1 (es) 1999-12-17
MY121743A (en) 2006-02-28
KR20010031299A (ko) 2001-04-16
AU742166C (en) 2005-07-14
RU2330667C2 (ru) 2008-08-10
IL135742A (en) 2004-09-27
EP1032399A1 (en) 2000-09-06
RO121319B1 (ro) 2007-03-30
US6306914B1 (en) 2001-10-23
IL135742A0 (en) 2001-05-20
RU2261099C2 (ru) 2005-09-27
AU1191499A (en) 1999-05-10
HUP0004133A2 (hu) 2001-05-28
US6593317B1 (en) 2003-07-15
CN1147301C (zh) 2004-04-28
CA2307615A1 (en) 1999-04-29
NZ504066A (en) 2002-11-26
RU2005101612A (ru) 2006-07-10
US20010031747A1 (en) 2001-10-18
NO326856B1 (no) 2009-03-02
WO1999020282A1 (en) 1999-04-29
HUP0004133A3 (en) 2001-09-28
MXPA00003972A (es) 2004-04-21
CN1282250A (zh) 2001-01-31
BR9813262A (pt) 2000-08-22
AU742166B2 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
AR013981A1 (es) Terapia de progestina con hemorragia controlada
CO4290332A1 (es) Nuevo metodo de suministro de progesterona y el efecto del mismo
ES2053105T3 (es) Emulsion formadora de peliculas que contiene yodo y metodos de uso.
ES2193146T3 (es) Composicion farmaceutica con inicio de liberacion y velocidad de liberacion controlados.
AR006484A1 (es) Composición farmacéutica con efecto anestésico, uso de esta composición para la fabricación de medicamentos, y proceso para la fabricación de esta composición .
ES2163554T3 (es) Neumatico que comprende cables circunferenciales, para anclar la carcasa, y procedimiento de preparacion de dichos cables.
CO5261492A1 (es) Formas de dosificacion de liberacion controlada que comprenden zolpidem o sales del mismo
ES2149264T3 (es) Agente terapeutico para el tratamiento de melanomas.
ES2111547T3 (es) Comprimido de liberacion prolongada.
AR022148A1 (es) ARTíCULO ABSORBENTE Y MÉTODO PARA FABRICAR UNA ESTRUCTURA ABSORBENTE.
AR032352A1 (es) Composicion farmaceutica bioadhesiva de hidratacion gradual y su uso en la fabricacion de un medicamento para la administracion de testosterona y terbutalina a un mamifero a traves de una superficie de mucosa.
CO5150210A1 (es) Tratamiento de bph con agentes elevadores del cgmp
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
ES2116451T3 (es) Dispensador de fluidos.
ES2038807T3 (es) Protesis dilatable para correcciones de miodistrofias.
CO5631449A2 (es) Nuevos esteres de etonogestrel
GB8711058D0 (en) Combination
FI833018A0 (fi) Laekemedelsblandad suppositorium
ES2173485T3 (es) Anestesico local para uso externo.
ES2109131B1 (es) Composicion farmaceutica que tiene actividad analgesica.
SE8800025D0 (sv) Bioadhesive suppository pharmaceutical preparations
CO4960650A1 (es) Composicion con agente emulsificador de copolimero reticulado de acrilato /c10/c30 alquilo acrilato
CO5200833A1 (es) Regimenes de dosificacion para lasofoxifeno
ATE359066T1 (de) Pflaster mit 4-biphenylessigsäure
ES2162433T3 (es) Procedimiento para el tratamiento del clinker de cemento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure